Mirum Pharmaceuticals (MIRM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.80
- Estimate
- -$0.75
- Surprise
- -7.4%
- Revenue (period 2026-06-30)
- $176.2M
- Score at report (before → after)
- 6.0 → 6.0/10
Revenue source: xbrl.
How the report landed
Mirum Pharmaceuticals (MIRM) reported a wider loss than forecast — adjusted EPS of -$0.80 against the -$0.75 estimate (a 7.4% shortfall). TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Sell at 6.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MIRM Sell at 6.3/10.
1 of the last 4 quarters beat the estimate; this quarter's -7.4% surprise compares with a -97.6% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Supplier: one specialty pharmacy
- Earnings in 5 days (event risk)
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $87.99
- Price target
- $133.48
- Stop
- $81.83
- Upside to target
- +51.7%
- Reward-to-risk
- 4.5:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
MIRM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.57B
- P/E (fwd)
- -121.7
- 52-week range
- $63.23–$130.00
- Off 52-week high
- 32.3%
- RSI (14)
- 53
- Volume vs avg
- 0.01×
- Score today
- 6.3/10